Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33


Borrelia miyamotoi Infection in Patients from Upper Midwestern United States, 2014-2015.

Jobe DA, Lovrich SD, Oldenburg DG, Kowalski TJ, Callister SM.

Emerg Infect Dis. 2016 Aug;22(8):1471-3. doi: 10.3201/eid2208.151878.


Detection of IFN-γ Secretion by T Cells Collected Before and After Successful Treatment of Early Lyme Disease.

Callister SM, Jobe DA, Stuparic-Stancic A, Miyamasu M, Boyle J, Dattwyler RJ, Arnaboldi PM.

Clin Infect Dis. 2016 May 15;62(10):1235-1241. doi: 10.1093/cid/ciw112. Epub 2016 Mar 1.


The Emergence of Clinically Relevant Babesiosis in Southwestern Wisconsin.

Kowalski TJ, Jobe DA, Dolan EC, Kessler A, Lovrich SD, Callister SM.

WMJ. 2015 Aug;114(4):152-7.


Antibody responses to Borrelia burgdorferi outer surface proteins C and F in experimentally infected Beagle dogs.

Callister SM, LaFleur RL, Jobe DA, Lovrich SD, Wasmoen TL.

J Vet Diagn Invest. 2015 Jul;27(4):526-30. doi: 10.1177/1040638715583868. Epub 2015 Jun 11.


Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.

LaFleur RL, Callister SM, Dant JC, Wasmoen TL, Jobe DA, Lovrich SD.

Clin Vaccine Immunol. 2015 Jul;22(7):836-9. doi: 10.1128/CVI.00193-15. Epub 2015 May 13.


ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Go RS, Lee SJ, Shin D, Callister SM, Jobe DA, Conry RM, Tarhini AA, Kirkwood JM.

Clin Cancer Res. 2013 Dec 1;19(23):6597-604. doi: 10.1158/1078-0432.CCR-13-1414. Epub 2013 Oct 11.


Expansion of the Midwestern focus for human granulocytic anaplasmosis into the region surrounding La Crosse, Wisconsin.

Lovrich SD, Jobe DA, Kowalski TJ, Policepatil SM, Callister SM.

J Clin Microbiol. 2011 Nov;49(11):3855-9. doi: 10.1128/JCM.05025-11. Epub 2011 Sep 14.


Rapid decline of OspC borreliacidal antibodies following treatment of patients with early Lyme disease.

Jobe DA, Kowalski TJ, Bloemke M, Lovrich SD, Callister SM.

Clin Vaccine Immunol. 2011 Jun;18(6):1034-7. doi: 10.1128/CVI.00063-11. Epub 2011 Apr 20.


One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin.

LaFleur RL, Callister SM, Dant JC, Jobe DA, Lovrich SD, Warner TF, Wasmoen TL, Schell RF.

Clin Vaccine Immunol. 2010 May;17(5):870-4. doi: 10.1128/CVI.00524-09. Epub 2010 Mar 17.


Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.

LaFleur RL, Dant JC, Wasmoen TL, Callister SM, Jobe DA, Lovrich SD, Warner TF, Abdelmagid O, Schell RF.

Clin Vaccine Immunol. 2009 Feb;16(2):253-9. doi: 10.1128/CVI.00373-08. Epub 2008 Dec 3.


Detection of borreliacidal antibodies by flow cytometry.

Callister SM, Jobe DA, Schell RF.

Curr Protoc Cytom. 2004 Nov;Chapter 11:Unit 11.5. doi: 10.1002/0471142956.cy1105s26.


Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of Borrelia burgdorferi OspC.

Jobe DA, Lovrich SD, Asp KE, Mathiason MA, Albrecht SE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2008 Jun;15(6):981-5. doi: 10.1128/CVI.00079-08. Epub 2008 Apr 16.


Lyme disease in urban areas, Chicago.

Jobe DA, Nelson JA, Adam MD, Martin SA Jr.

Emerg Infect Dis. 2007 Nov;13(11):1799-800. doi: 10.3201/eid1311.070801. No abstract available.


Circulating endothelial cells in patients with chronic lymphocytic leukemia.

Go RS, Jobe DA, Asp KE, Callister SM, Mathiason MA, Meyer LA, Bottner WA, Cole CE, Farnen JP, Frisby KA.

Ann Hematol. 2008 May;87(5):369-73. doi: 10.1007/s00277-007-0435-y. Epub 2008 Jan 12.


Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease.

Lovrich SD, La Fleur RL, Jobe DA, Johnson JC, Asp KE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2007 May;14(5):635-7. Epub 2007 Mar 7.


Borrelia burgdorferi in Ixodes scapularis ticks, Chicago area.

Jobe DA, Lovrich SD, Nelson JA, Velat TC, Anchor C, Koeune T, Martin SA Jr.

Emerg Infect Dis. 2006 Jun;12(6):1039-41. No abstract available.


Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Lovrich SD, Jobe DA, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2005 Jun;12(6):746-51. Erratum in: Clin Diagn Lab Immunol. 2005 Sep;12(9):1139.


C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Jobe DA, Lovrich SD, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2003 Jul;10(4):573-8.


Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Callister SM, Jobe DA, Agger WA, Schell RF, Kowalski TJ, Lovrich SD, Marks JA.

Clin Diagn Lab Immunol. 2002 Jul;9(4):908-12.


Detection of borreliacidal antibodies in dogs after challenge with Borrelia burgdorferi-infected ixodes scapularis ticks.

Callister SM, Jobe DA, Schell RF, Lovrich SD, Onheiber KL, Korshus JB.

J Clin Microbiol. 2000 Oct;38(10):3670-4.


Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

Munson EL, Du Chateau BK, Jobe DA, Lovrich SD, Callister SM, Schell RF.

Infect Immun. 2000 Oct;68(10):5496-501.


Evaluation of whole-cell and OspC enzyme-linked immunosorbent assays for discrimination of early lyme borreliosis from OspA vaccination.

Wieneke CA, Lovrich SD, Callister SM, Jobe DA, Marks JA, Schell RF.

J Clin Microbiol. 2000 Jan;38(1):313-7.


Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Jobe DA, Rawal N, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 1999 Nov;6(6):930-3.


Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi.

Rousselle JC, Callister SM, Schell RF, Lovrich SD, Jobe DA, Marks JA, Wieneke CA.

J Infect Dis. 1998 Sep;178(3):733-41.


Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine.

Padilla ML, Callister SM, Schell RF, Bryant GL, Jobe DA, Lovrich SD, DuChateau BK, Jensen JR.

J Infect Dis. 1996 Oct;174(4):739-46.


Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

Callister SM, Jobe DA, Schell RF, Pavia CS, Lovrich SD.

Clin Diagn Lab Immunol. 1996 Jul;3(4):399-402.


Detection of borreliacidal antibodies by flow cytometry. An accurate, highly specific serodiagnostic test for Lyme disease.

Callister SM, Schell RF, Lim LC, Jobe DA, Case KL, Bryant GL, Molling PE.

Arch Intern Med. 1994 Jul 25;154(14):1625-32.


Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi.

Lim LC, England DM, DuChateau BK, Glowacki NJ, Creson JR, Lovrich SD, Callister SM, Jobe DA, Schell RF.

Infect Immun. 1994 Jul;62(7):2825-33.


Ability of canine Lyme disease vaccine to protect hamsters against infection with several isolates of Borrelia burgdorferi.

Jobe DA, Callister SM, Lim LC, Lovrich SD, Schell RF.

J Clin Microbiol. 1994 Mar;32(3):618-22.


Lyme disease: laboratory diagnosis and serologic testing.

Callister SM, Schell RF, Lovrich SD, Jobe DA.

Endeavour. 1994;18(2):80-4. Review.


Recovery of Borrelia burgdorferi by filtration.

Jobe DA, Callister SM, Schell RF.

J Clin Microbiol. 1993 Jul;31(7):1896-8.


In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.

Agger WA, Callister SM, Jobe DA.

Antimicrob Agents Chemother. 1992 Aug;36(8):1788-90.


Survey for Ixodes spp. and Borrelia burgdorferi in southeastern Wisconsin and northeastern Illinois.

Callister SM, Nelson JA, Schell RF, Jobe DA, Bautz R, Agger WA, Coggins J.

J Clin Microbiol. 1991 Feb;29(2):403-6.

Supplemental Content

Support Center